Evidence map›Paper›PMID 40275390›Full record

ArticleHereditary cancer in clinical practice2025

Chemotherapy receipt in affected BRCA1/2 and PALB2 carriers with operable breast cancer: the impact of early detection and pre-diagnostic awareness on clinical outcomes and treatment.

Stephanie M Wong, Carla Apostolova, Amina Ferroum, Basmah Alhassan, Ipshita Prakash, Mark Basik, Karyne Martel, Sarkis Meterissian, David Fleiszer, Nora Wong and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hereditary cancer in clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stephanie M WongDepartment of Surgery, McGill University, Montreal, QC, Canada. sm.wong@mcgill.ca.
Carla ApostolovaDepartment of Surgery, McGill University, Montreal, QC, Canada.
Amina FerroumDepartment of Surgery, McGill University, Montreal, QC, Canada.
Basmah AlhassanDepartment of Surgery, McGill University, Montreal, QC, Canada.
Ipshita PrakashDepartment of Surgery, McGill University, Montreal, QC, Canada.
Mark BasikDepartment of Surgery, McGill University, Montreal, QC, Canada.
Karyne MartelDepartment of Surgery, McGill University, Montreal, QC, Canada.
Sarkis MeterissianDepartment of Surgery, McGill University, Montreal, QC, Canada.
David FleiszerDepartment of Surgery, McGill University, Montreal, QC, Canada.
Nora WongStroll Cancer Prevention Centre, Jewish General Hospital, Montreal, QC, Canada.
Michaela Bercovitch SadinskyStroll Cancer Prevention Centre, Jewish General Hospital, Montreal, QC, Canada.
Talia MalagonDepartment of Oncology, McGill University, Montreal, QC, Canada.
Jean Francois BoileauDepartment of Surgery, McGill University, Montreal, QC, Canada.
William D FoulkesStroll Cancer Prevention Centre, Jewish General Hospital, Montreal, QC, Canada.

Funding

Fonds de Recherche du Québec - Santé 309854
6 · The paper itself

Abstract

purposeWhile enhanced breast screening of germline pathogenic variant (GPV) carriers results in earlier stage at diagnosis, the impact of tumour biology and GPV on chemotherapy receipt in early-stage disease remains understudied.

methodsWe retrospectively reviewed treatment administered following a first diagnosis of BRCA1/2- and PALB2-associated breast cancer between 2002 and 2022. Chemotherapy receipt was compared according to tumor size, biologic subtype, and GPV. Subgroup analyses were performed in women with T1N0 disease and in those with pre-diagnostic awareness of their GPV.

resultsOverall, 309 affected BRCA1/2 and PALB2 carriers with a median age of 43 years at breast cancer diagnosis (range, 19-80 years) were included; 160 (51.8%) BRCA1, 130 (42.1%) BRCA2, and 19 (6.1%) PALB2 carriers. Chemotherapy was administered in 70.9% of index breast cancer cases and was significantly associated with younger age, tumor size, histologic grade, nodal status, and biologic subtype (all p < 0.05). Chemotherapy receipt was 80.6% in BRCA1-associated breast cancers compared to 56.9% in BRCA2 and 84.2% in PALB2 associated breast cancers (p < 0.001). In subgroup analysis of early stage, T1N0 disease, chemotherapy was administered in 78.9% BRCA1 and 59.5% BRCA2/PALB2 patients (p = 0.04). Pre-diagnostic awareness of a GPV in BRCA1/2 or PALB2 was associated with smaller invasive tumors (%T1, 50% vs. 32.9%; p = 0.002) and node-negative invasive disease (87.1% vs. 72.2%), as well as a reduced likelihood of chemotherapy (59.7% vs. 74.3%, p = 0.02).

conclusionChemotherapy receipt is high in BRCA1/2 and PALB2-associated breast cancers including in early stage, node-negative disease. Pre-diagnostic awareness is associated with a lower likelihood of requiring chemotherapy for a breast cancer diagnosis.

Indexed as

BRCA1/2Breast neoplasmsChemotherapyHereditary breast cancer

Identifiers

PMID40275390
PMCPMC12020017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.